NOVA Plans 26% Owner Emission Share to Fund Drug-Discovery Lab Data
Metanova will direct additional owner emissions into experimental datasets, starting with an ADME model-training competition.
Metanova
Metanova Builds NOVA Drug-Optimization Agent With Chutes and Onepot AI
The system will help researchers refine small molecules while keeping proprietary drug-discovery data confidential.
Metanova Starts Nanobody Validation With Yalotein as NOVA Expands Beyond Small Molecules
The Bittensor SN68 project is moving nanobody submissions toward wet-lab testing as NOVA expands its drug-discovery pipeline beyond small molecules.
Metanova (SN68): How Bittensor's Drug Discovery Subnet Answered Pharma's Billion-Dollar AI Race
While Isomorphic Labs, GSK, and Anthropic poured billions into closed AI drug discovery platforms, Metanova (SN68) spent H1 2026 screening 11 million molecules in the open, tightening its incentives, and cutting synthesis time from months to days.
Metanova Partners With ONEPOT.AI to Accelerate Drug Discovery on Bittensor
Metanova partners with ONEPOT.AI to accelerate drug discovery on Bittensor, enabling SN68-generated compounds to move from AI screening to robotic synthesis in days.